

REFERENCES

- Arora, A., & Somasundaram, K. (2019). Glioblastoma vs temozolomide: can the red queen race be won?. *Cancer biology & therapy*, 20(8), 1083–1090. <https://doi.org/10.1080/15384047.2019.1599662>
- Baenke, F., Chaneton, B., Smith, M., Van Den Broek, N., Hogan, K., Tang, H., Viros, A., Martin, M., Galbraith, L., Girotti, M. R., Dhomen, N., Gottlieb, E., & Marais, R. (2016). Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. *Molecular oncology*, 10(1), 73–84. <https://doi.org/10.1016/j.molonc.2015.08.003>
- Becker, A. P., Sells, B. E., Haque, S. J., & Chakravarti, A. (2021). Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. *Cancers*, 13(4), 761. <https://doi.org/10.3390/cancers13040761>
- Brix, N., Samaga, D., Hennel, R., Gehr, K., Zitzelsberger, H., & Lauber, K. (2020). The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation. *Radiation Oncology*, 15, 1-12. <https://doi.org/10.1186/s13014-020-01697-y>
- Brodbelt, A., Greenberg, D., Winters, T., Williams, M., Vernon, S., Collins, V. P., & (UK) National Cancer Information Network Brain Tumour Group (2015). Glioblastoma in England: 2007-2011. *European journal of cancer (Oxford, England : 1990)*, 51(4), 533–542. <https://doi.org/10.1016/j.ejca.2014.12.014>
- Chang, K. Y., Hsu, T. I., Hsu, C. C., Tsai, S. Y., Liu, J. J., Chou, S. W., Liu, M. S., Liou, J. P., Ko, C. Y., Chen, K. Y., Hung, J. J., Chang, W. C., Chuang, C. K., Kao, T. J., & Chuang, J. Y. (2017). Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. *Redox biology*, 13, 655–664. <https://doi.org/10.1016/j.redox.2017.08.005>
- Davis, M. E. (2016). Glioblastoma: Overview of Disease and Treatment. *Clinical journal of oncology nursing*, 20(5 Suppl), S2–S8. <https://doi.org/10.1188/16.CJON.S1.2-8>
- Di Filippo, L. D., Azambuja, J. H., Dutra, J. A. P., Luiz, M. T., Duarte, J. L., Nicoletti, L. R., ... & Chorilli, M. (2021). Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. *European Journal of Pharmaceutics and Biopharmaceutics*, 168, 76-89. <https://doi.org/10.1016/j.ejpb.2021.08.011>
- Eisenbarth, D., & Wang, Y. A. (2023). Glioblastoma heterogeneity at single cell resolution. *Oncogene*, 42, 2155-2165. <https://doi.org/10.1038/s41388-023-02738-y>
- Ekici, S., Nye, J. A., Neill, S. G., Allen, J. W., Shu, H. K., & Fleischer, C. C. (2022). Glutamine imaging: a new avenue for glioma management. *American Journal of Neuroradiology*, 43(1), 11-18. <https://doi.org/10.3174/ajnr.A7333>

- Fabbro-Peray, P., Zouaoui, S., Darlix, A., Fabbro, M., Pallud, J., Rigau, V., Mathieu-Daude, H., Bessaoud, F., Bauchet, F., Riondel, A., Sorbets, E., Charissoux, M., Amelot, A., Mandonnet, E., Figarella-Branger, D., Duffau, H., Tretarre, B., Taillandier, L., & Bauchet, L. (2019). Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. *Journal of neuro-oncology*, *142*(1), 91–101. <https://doi.org/10.1007/s11060-018-03065-z>
- Faustino, A. C., Viani, G. A., & Hamamura, A. C. (2020). Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. *Clinics*, *75*. <https://doi.org/10.6061/clinics/2020/e1553>
- Gerritsen, J. K. W., Broekman, M. L. D., De Vleeschouwer, S., Schucht, P., Nahed, B. V., Berger, M. S., & Vincent, A. J. P. E. (2022). Safe surgery for glioblastoma: Recent advances and modern challenges. *Neuro-oncology practice*, *9*(5), 364-379. <https://doi.org/10.1093/nop/npac019>
- Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. *International journal of molecular sciences*, *22*(23), 12827. <https://doi.org/10.3390/ijms222312827>
- Ghosh, R., Gilda, J. E., & Gomes, A. V. (2014). The necessity of and strategies for improving confidence in the accuracy of western blots. *Expert review of proteomics*, *11*(5), 549–560. <https://doi.org/10.1586/14789450.2014.939635>
- Gittleman, H., Boscia, A., Ostrom, Q. T., Truitt, G., Fritz, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2018). Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. *Neuro-oncology*, *20*(suppl_7), vii6–vii16. <https://doi.org/10.1093/neuonc/noy090>
- Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020). Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. *Cureus*, *12*(5), e8195. <https://doi.org/10.7759/cureus.8195>
- Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022). Epidemiology of glioblastoma multiforme—literature review. *Cancers*, *14*(10), 2412. <https://doi.org/10.3390/cancers14102412>
- Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017). Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pacific journal of cancer prevention : APJCP*, *18*(1), 3–9. <https://doi.org/10.22034/APJCP.2017.18.1.3>
- Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013). Glutamine and cancer: cell biology, physiology, and clinical opportunities. *The Journal of clinical investigation*, *123*(9), 3678-3684. <https://doi.org/10.1172/JCI69600>
- Jozefczak, M., Remans, T., Vangronsveld, J., & Cuyper, A. (2012). Glutathione is a key player in metal-induced oxidative stress defenses. *International journal of molecular sciences*, *13*(3), 3145-3175. <https://doi.org/10.3390/ijms13033145>

- Kanderi, T., & Gupta, V. (2022). Glioblastoma multiforme. In *StatPearls* [Internet]. StatPearls Publishing.
- Kim, H. J., Shaker, M. R., Cho, B., Cho, H. M., Kim, H., Kim, J. Y., & Sun, W. (2015). Dynamin-related protein 1 controls the migration and neuronal differentiation of subventricular zone-derived neural progenitor cells. *Scientific reports*, *5*, 15962. <https://doi.org/10.1038/srep15962>
- Lafita-Navarro, M. C., Venkateswaran, N., Kilgore, J. A., Kanji, S., Han, J., Barnes, S., Williams, N. S., Buszczak, M., Burma, S., & Conacci-Sorrell, M. (2020). Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells. *PLoS genetics*, *16*(11), e1009117. <https://doi.org/10.1371/journal.pgen.1009117>
- Lai, S. W., Huang, B. R., Liu, Y. S., Lin, H. Y., Chen, C. C., Tsai, C. F., ... & Lin, C. (2018). Differential characterization of temozolomide-resistant human glioma cells. *International journal of molecular sciences*, *19*(1), 127. <https://doi.org/10.3390/ijms19010127>
- Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme. *Genes & diseases*, *3*(3), 198–210. <https://doi.org/10.1016/j.gendis.2016.04.007>
- Leguina-Ruzzi, A., & Cariqueo, M. (2017). Glutamine: a conditionally essential amino acid with multiple biological functions. In *Superfood and Functional Food-The Development of Superfoods and Their Roles as Medicine*. IntechOpen.
- Liu, X., Wang, Y., Yang, W., Guan, Z., Yu, W., & Liao, D. J. (2016). Protein multiplicity can lead to misconduct in western blotting and misinterpretation of immunohistochemical staining results, creating much conflicting data. *Progress in histochemistry and cytochemistry*, *51*(3-4), 51–58. <https://doi.org/10.1016/j.proghi.2016.11.001>
- Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. *North American journal of medical sciences*, *4*(9), 429–434. <https://doi.org/10.4103/1947-2714.100998>
- McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., ... & Stordal, B. (2014). In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. *Frontiers in oncology*, *4*, 40. <https://doi.org/10.3389/fonc.2014.00040>
- Noch, E. K., Ramakrishna, R., & Magge, R. (2018). Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance. *World neurosurgery*, *116*, 505-517. <https://doi.org/10.1016/j.wneu.2018.04.022>
- Obara-Michlewska, M., & Szeliga, M. (2020). Targeting Glutamine Addiction in Gliomas. *Cancers*, *12*(2), 310. <https://doi.org/10.3390/cancers12020310>

- Ou, A., Ott, M., Fang, D., & Heimberger, A. B. (2021). The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. *Cancers*, *13*(3), 437. <https://doi.org/10.3390/cancers13030437>
- Pasqualato, A., Palombo, A., Cucina, A., Mariggìo, M. A., Galli, L., Passaro, D., Dinicola, S., Proietti, S., D'Anselmi, F., Coluccia, P., & Bizzarri, M. (2012). Quantitative shape analysis of chemoresistant colon cancer cells: correlation between morphotype and phenotype. *Experimental cell research*, *318*(7), 835–846. <https://doi.org/10.1016/j.yexcr.2012.01.022>
- Pilmack, E. R., Lorusso, P. M., McCoon, P., Tang, W., Krebs, A. D., Curt, G., & Eckhardt, S. G. (2013). AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. *The oncologist*, *18*(7), 819–820. <https://doi.org/10.1634/theoncologist.2013-0198>
- Prasad, A., & Alizadeh, E. (2019). Cell form and function: interpreting and controlling the shape of adherent cells. *Trends in biotechnology*, *37*(4), 347-357. <https://doi.org/10.1016/j.tibtech.2018.09.007>
- Quek, L. E., van Geldermalsen, M., Guan, Y. F., Wahi, K., Mayoh, C., Balaban, S., ... & Holst, J. (2022). Glutamine addiction promotes glucose oxidation in triple-negative breast cancer. *Oncogene*, *41*(34), 4066-4078. <https://doi.org/10.1038/s41388-022-02408-5>
- Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., McLendon, R. E., Herndon, J. E., 2nd, Walker, A., & Friedman, H. S. (2009). Phase II trial of temozolomide plus α 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, *27*(8), 1262–1267. <https://doi.org/10.1200/JCO.2008.18.8417>
- Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., Mikkelsen, T., Wang, D., Chang, Y. C., Hu, J., McAfee, Q., Fisher, J., Troxel, A. B., Piao, S., Heitjan, D. F., Tan, K. S., Pontiggia, L., O'Dwyer, P. J., Davis, L. E., & Amaravadi, R. K. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. *Autophagy*, *10*(8), 1359–1368. <https://doi.org/10.4161/auto.28984>
- Sani, S., Pallaoro, N., Messe, M., Bernhard, C., Etienne-Selloum, N., Kessler, H., Marinelli, L., Entz-Werle, N., Foppolo, S., Martin, S., Reita, D., & Dontenwill, M. (2022). Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α 5 β 1 Integrin. *Cancers*, *14*(2), 369. <https://doi.org/10.3390/cancers14020369>
- Shergalis, A., Bankhead, A., 3rd, Luesakul, U., Muangsin, N., & Neamati, N. (2018). Current Challenges and Opportunities in Treating Glioblastoma. *Pharmacological reviews*, *70*(3), 412–445. <https://doi.org/10.1124/pr.117.014944>
- Storey, K., Leder, K., Hawkins-Daarud, A., Swanson, K., Ahmed, A. U., Rockne, R. C., & Foo, J. (2019). Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation. *JCO clinical cancer informatics*, *3*, 1–12. <https://doi.org/10.1200/CCI.18.00062>

- Suarez-Arnedo, A., Torres Figueroa, F., Clavijo, C., Arbeláez, P., Cruz, J. C., & Muñoz-Camargo, C. (2020). An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. *PLoS one*, *15*(7), e0232565.
- Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020). Management of glioblastoma: State of the art and future directions. *CA: a cancer journal for clinicians*, *70*(4), 299-312. <https://doi.org/10.3322/caac.21613>
- Tang, H., Zeng, L., Wang, J., Zhang, X., Ruan, Q., Wang, J., ... & Yang, D. (2017). Reversal of 5-fluorouracil resistance by EGCG is mediated by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. *Oncotarget*, *8*(47), 82842. <https://doi.org/10.18632/oncotarget.20666>
- Tardito, S., Oudin, A., Ahmed, S. U., Fack, F., Keunen, O., Zheng, L., Miletic, H., Sakariassen, P. Ø., Weinstock, A., Wagner, A., Lindsay, S. L., Hock, A. K., Barnett, S. C., Ruppin, E., Mørkve, S. H., Lund-Johansen, M., Chalmers, A. J., Bjerkvig, R., Niclou, S. P., & Gottlieb, E. (2015). Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. *Nature cell biology*, *17*(12), 1556–1568. <https://doi.org/10.1038/ncb3272>
- Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019). Glioblastoma multiforme: an overview of emerging therapeutic targets. *Frontiers in oncology*, *9*, 963. <https://doi.org/10.3389/fonc.2019.00963>
- Tiek, D. M., Rone, J. D., Graham, G. T., Pannkuk, E. L., Haddad, B. R., & Riggins, R. B. (2018). Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. *Scientific reports*, *8*(1), 7222. <https://doi.org/10.1038/s41598-018-25588-1>
- Tong, S., Wang, Y., Wu, J., Long, J., Zhong, P., & Wang, B. (2021). Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. *European Journal of Pharmacology*, *912*, 174580. <https://doi.org/10.1016/j.ejphar.2021.174580>
- Tsai, Y. T., Lo, W. L., Chen, P. Y., Ko, C. Y., Chuang, J. Y., Kao, T. J., ... & Hsu, T. I. (2022). Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation. *Journal of Biomedical Science*, *29*(1), 21. <https://doi.org/10.1186/s12929-022-00804-3>
- van den Heuvel, A. P., Jing, J., Wooster, R. F., & Bachman, K. E. (2012). Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. *Cancer biology & therapy*, *13*(12), 1185–1194. <https://doi.org/10.4161/cbt.21348>
- van Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., van de Ven, P. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., Walenkamp, A. M. E., & Verheul, H. M. W. (2017). Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. *Journal of neuro-oncology*, *135*(1), 183–192. <https://doi.org/10.1007/s11060-017-2564-z>

- Wakabayashi, T., Natsume, A., Mizusawa, J., Katayama, H., Fukuda, H., Sumi, M., Nishikawa, R., Narita, Y., Muragaki, Y., Maruyama, T., Ito, T., Beppu, T., Nakamura, H., Kayama, T., Sato, S., Nagane, M., Mishima, K., Nakasu, Y., Kurisu, K., Yamasaki, F., ... Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG) (2018). JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon β plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. *Journal of neuro-oncology*, 138(3), 627–636. <https://doi.org/10.1007/s11060-018-2831-7>
- Xu, Y., Yang, X., Mei, S., Sun, Y., & Li, J. (2019). Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype. *Oncology reports*, 42(6), 2355–2362. <https://doi.org/10.3892/or.2019.7350>
- Xuan, D. T. M., Anuraga, G., Ta, H. D. K., Chiao, C. C., Dey, S., & Wang, C. Y. (2023). *Investigating potential therapeutic targets of amino acid metabolism in temozolomide-resistance and relapse glioblastoma patients* [Unpublished manuscript]. Taipei Medical University.
- Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020). Glutamine reliance in cell metabolism. *Experimental & molecular medicine*, 52(9), 1496-1516. <https://doi.org/10.1038/s12276-020-00504-8>
- Yoon, W. S., Chang, J. H., Kim, J. H., Kim, Y. J., Jung, T. Y., Yoo, H., ... & Yang, S. H. (2023). Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study). *Discover Oncology*, 14(1), 90. <https://doi.org/10.1007/s12672-023-00678-3>
- Zeng, H., Xu, N., Liu, Y., Liu, B., Yang, Z., Fu, Z., Lian, C., & Guo, H. (2017). Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. *International journal of oncology*, 51(2), 445–455. <https://doi.org/10.3892/ijo.2017.4033>
- Zhang, J., Stevens, M. F., & Bradshaw, T. D. (2012). Temozolomide: mechanisms of action, repair and resistance. *Current molecular pharmacology*, 5(1), 102–114. <https://doi.org/10.2174/1874467211205010102>
- Zhong, X., He, Z., Yin, L., Fan, Y., Tong, Y., Kang, Y., & Bi, Q. (2023). Glutamine metabolism in tumor metastasis: Genes, mechanisms and the therapeutic targets. *Heliyon*, 9(10), e20656. <https://doi.org/10.1016/j.heliyon.2023.e20656>